COMP <GO>
KYMR vs MRK // NET PROFIT MARGIN
Kymera Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: KYMR 4
— MRK 10
▲ NET PROFIT MARGIN LEADER: KYMR
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
net-margins
68.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.00% | 74.80% | -74.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 20.70% | -42.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 3.42% | -5.72 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 68.00% | 28.10% | +39.90 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 1.30% | -18.00 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.3 | 56.9 | +12.47 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 18.4x | +12.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $361.02B | -$350.83B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | MRK REV | KYMR GROSS % | MRK GROSS % | KYMR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $65.01B | 0.0% | 74.8% | -$234.3M | $12.36B |
| FY 2024 | $47.1M | $64.17B | 0.0% | 76.3% | -$207.3M | $18.10B |
| FY 2023 | $78.6M | $60.12B | 44.0% | 44.0% | -$106.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
MRK // BETA 0.92